News Sarepta rises after FDA adds warning label to Elevidys Uncertainty ends Sarepta's Duchenne gene therapy Elevidys ends after an FDA label update, with the company's shares on the up despite restrictions.
News Intellia shares fall after hospitalised CRISPR patient dies Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.
News CRISPR biotech Intellia plummets as trial paused for safety Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.
News FDA will review abortion pill safety – will it be impartial? The Trump administration's linking of autism to Tylenol and vaccines with no evidence raises concern about an FDA review of mifepristone's safety.
News Intercept pulls Ocaliva off the market in the US Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.
News RFK Jr revives childhood vaccine task force HHS Secretary Kennedy adds yet another layer of scrutiny to childhood vaccines with the re-establishment of a task force disbanded in the 1990s.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.